Artery Elasticity After Switch From Epzicom to Truvada

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00998582

Recruitment Status : Terminated (Low enrollment)

First Posted : October 20, 2009

Results First Posted : March 23, 2012

Last Update Posted : October 8, 2012

Sponsor:

Information provided by (Responsible Party):

Minneapolis Medical Research Foundation

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	HIV Infections
Intervention:	Drug: Tenofovir disoproxil

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Abacavir	Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
Tenofovir	Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
Total	Total of all reporting groups

Baseline Measures

	Abacavir	Tenofovir	Total
Overall Participants Analyzed [Units: Participants]	13	14	27

Age [Units: Participants]
<=18 years	0	0	0
Between 18 and 65 years	13	14	27
>=65 years	0	0	0

Age [Units: Years] Mean (Standard Deviation)	47 (7)	43 (9)	46 (8)

Gender [Units: Participants]
Female	1	0	1
Male	12	14	26

Region of Enrollment [Units: Participants]
United States	13	14	27